Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 8

Abstract

Background: The objective of this study is to provide certain data on clinical outcomes and their predictors of traditional maximum androgen blockade (MAB) in prostate cancer with bone metastasis. Methods: Subjects were patients with prostate adenocarcinoma with bone metastasis initiated to treat with MAB as a primary treatment without any local therapy at our hospital between January 2003 and December 2010. Time to prostate specific antigen (PSA) progression, overall survival (OS) time, and association of clinical factors and outcomes were retrospectively evaluated. Results: A total of 57 patients were evaluable. The median age was 70 years. The median primary PSA was 203 ng/ml. Luteinizing hormone-releasing hormone agonists had been administered in 96.5% of the patients. Bicalutamide had been chosen in 89.4 % of the patients as the initial antiandrogen. The median time to PSA progression with MAB was 11.3 months (95% confidence interval [CI], 10.4 to 13.0). The median OS was 47.3 months (95% CI, 30.7 to 81.0). Gleason score 9 or greater, decline of PSA level equal to or higher than 1.0 ng/ml with MAB, and time to PSA nadir equal to or shorter than six months after initiation of MAB were independent risk factors for time to PSA progression (P=0.010, P=0.005, and P=0.001; respectively). Time to PSA nadir longer than six months was the only independent predictor for longer OS (HR, 0.255 [95% CI, 0.109 to 0.597]; P=0.002). Conclusions: Initial time to PSA nadir should be emphasized for clinical outcome analyses in future studies on prostate cancer with bone metastasis.

Authors and Affiliations

Yamamoto Y, Nozawa M, Itami Y, Kobayashi Y, Saito Y, Shimizu N, Minami T, Hayashi T, Tsuji H, Yoshimura K, Ishii T, Uemura H

Keywords

Related Articles

Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells

Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy. Aberrant promoter DNA methylation can result in the epigenetic silencing of tumor suppress...

18F-FDG PET/CT for first follow-up post chemotherapy in lymphoma: Is it mandatory to do whole body scan?

Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scan limited to the original sites of lymphoma in 1st follow-up (F/U) post-chemotherapy...

Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis

Objectives: To develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria i...

A clinical study on stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Purposes: Hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT) has a poor prognosis, while the optimal treatment remains controversial. The objective of this retrospective study was to evaluate the effic...

A single center series highlights on incidence and management of gastric neuroendocrine tumours with literature review

Neuroendocrine tumours of the digestive system (GEP-NET) are relatively rare. Nevertheless, their diagnoses is rising as seen from studies in the US and elsewhere. Gastric neuroendocrine tumours (Gastric NETs) vary throu...

Download PDF file
  • EP ID EP551739
  • DOI 10.14312/2052-4994.2013-30
  • Views 83
  • Downloads 0

How To Cite

Yamamoto Y, Nozawa M, Itami Y, Kobayashi Y, Saito Y, Shimizu N, Minami T, Hayashi T, Tsuji H, Yoshimura K, Ishii T, Uemura H (2013). Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy. Journal of Cancer Research & Therapy, 1(8), 201-207. https://europub.co.uk./articles/-A-551739